Loading...
Pfizer Healthcare India Private Limited — Furosemide Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #4 for Furosemide · $650.0K export value · DGFT Verified
Pfizer Healthcare India Private Limited is the #4 Indian exporter of Furosemide with $650.0K in export value and 13 verified shipments. Pfizer Healthcare India Private Limited holds a 0.9% market share in Furosemide exports across 1 countries. The company exports 2 pharmaceutical products worth $2.2M across 2 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $42.5M | 2,058 | 66.6% |
| CANADA | $5.1M | 103 | 8.0% |
| FRANCE | $4.3M | 156 | 6.8% |
| GERMANY | $2.1M | 66 | 3.2% |
| SOUTH AFRICA | $1.6M | 47 | 2.5% |
| TANZANIA | $1.6M | 55 | 2.5% |
| MALTA | $1.4M | 106 | 2.1% |
| AUSTRALIA | $1.2M | 59 | 1.9% |
| SRI LANKA | $930.0K | 44 | 1.5% |
| NETHERLANDS | $650.7K | 129 | 1.0% |
India exports Furosemide to 150 countries. The top destination is UNITED STATES (66.6%), followed by CANADA and FRANCE.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| RISING PHARMA HOLDINGS, INC. | UNITED STATES | $6.3M | 969 |
| RISING PHARMA HOLDINGS INC | UNITED STATES | $4.2M | 373 |
| RISING PHARMA HOLDINGS INC,., | UNITED STATES | $3.6M | 369 |
| BAXTER HEALTHCARE CORPORATION | UNITED STATES | $3.1M | 62 |
| SALUTAS PHARMA GMBH |
India exported $43.6M worth of Furosemide through 4,657 shipments from 333 suppliers to 150 countries, serving 778 buyers globally. Pfizer Healthcare India Private Limited contributes $650.0K to this total, accounting for 0.9% of India's Furosemide exports.
Pfizer Healthcare India Private Limited's average Furosemide shipment value is $50.0K per consignment, based on 13 shipments totaling $650.0K.
Pfizer Healthcare India Private Limited ranks #4 among 333 Indian Furosemide exporters with a 0.9% market share. The top 3 exporters are GRAVITI PHARMACEUTICALS PRIVATE LIMITED ($14.3M), BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED ($7.1M), IPCA LABORATORIES LIMITED ($3.4M). Pfizer Healthcare India Private Limited processed 13 shipments to 1 destination countries.
What Pfizer Healthcare India Private Limited must comply with to export Furosemide to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 15 | GLAND PHARMA LTD | $995.3K | 28 | 4 | $35.5K |
| 10 | LINCOLN PHARMACEUTICALS LTD | $700.0K | 14 | 3 | $50.0K |
| 4 | PFIZER HEALTHCARE INDIA PRIVATE LIMITED ★ | $650.0K | 13 | 1 | $50.0K |
Pfizer Healthcare India Private Limited ranks #4 among 333 Indian Furosemide exporters. Average shipment value of $50.0K compared to the market average of $131.0K. The closest competitors by value are GLAND PHARMA LTD and LINCOLN PHARMACEUTICALS LTD.
| Port | Shipments | % Share |
|---|---|---|
| HYDERABAD ICD | 828 | 17.8% |
| HYDERABAD ICD (INSNF6) | 527 | 11.3% |
| SAHAR AIR | 417 | 9.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 401 | 8.6% |
| NHAVA SHEVA SEA (INNSA1) | 312 | 6.7% |
| ICD SANATHNAGAR, HYD | 162 | 3.5% |
| JNPT/ NHAVA SHEVA SEA | 137 | 2.9% |
| HYDERABAD AIR | 129 | 2.8% |
Pfizer Healthcare India Private Limited exports 2 products worth $2.2M. Beyond Furosemide, top products include Heparin. View the complete Pfizer Healthcare India Private Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Furosemide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Pfizer Healthcare India Private Limited's Furosemide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Pfizer Healthcare India Private Limited
Full Company Profile →
2 products · $2.2M total trade · 2 categories
| GERMANY |
| $2.1M |
| 64 |
| VIATRIS SANTE | FRANCE | $1.6M | 33 |
| AVET PHARMACEUTICALS INC. | UNITED STATES | $1.5M | 35 |
| MARCAN PHARMACEUTICALS INC., | CANADA | $1.2M | 24 |
| ATHENEX PHARMACEUTICAL DIVISION | UNITED STATES | $1.1M | 23 |
| HOSPIRA INC | UNITED STATES | $400.0K | 8 |
India's Furosemide is purchased by 778 buyers worldwide. The top buyer is RISING PHARMA HOLDINGS, INC. (UNITED STATES), followed by RISING PHARMA HOLDINGS INC and RISING PHARMA HOLDINGS INC,.,.
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 150+ countries, 778+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Pfizer Healthcare India Private Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Furosemide. For current shipment-level data, contact TransData Nexus.